Scarica l'app Stockscreener
131.42
4.52%
-6.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$137.64
Aprire:
$137.12
Volume 24 ore:
954.57K
Relative Volume:
1.34
Capitalizzazione di mercato:
$8.45B
Reddito:
$74.06M
Utile/perdita netta:
$-114.71M
Rapporto P/E:
-72.85
EPS:
-1.8039
Flusso di cassa netto:
$-117.90M
1 W Prestazione:
-0.15%
1M Prestazione:
+24.25%
6M Prestazione:
+63.82%
1 anno Prestazione:
+148.78%
Intervallo 1D:
$130.64
$137.12
Intervallo di 1 settimana:
$128.15
$141.10
Portata 52W:
$50.48
$141.10
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
131.42 | 8.45B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Protagonist Therapeutics (PTGX) AGM 2026 Summary - Quartr
Protagonist Therapeutics (PTGX) Investor Update Summary - Quartr
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review - Yahoo Finance
Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued - Yahoo Finance
Liquidity Mapping Around (PTGX) Price Events - Stock Traders Daily
New Strong Buy Stocks for July 9th - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest - simplywall.st
Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review FocusHas The Bull Case Changed? - Yahoo Finance
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains? - Yahoo Finance
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
Protagonist Therapeutics (PTGX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
PTGX climbs as target hike adds to late-stage pipeline optimism - Quiver Quantitative
PTGX Stock Grinds Higher As Pipeline Catalysts Build - StocksToTrade
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com India
Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies - ad-hoc-news.de
Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally - AlphaStreet
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? - TradingView
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $145 - Moomoo
PTGX Maintained by Truist Securities -- Price Target Raised to $145.00 - GuruFocus
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook - Investing.com
Price to sales forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX - TradingView
Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating - Moomoo
Protagonist Therapeutics Inc stock hits all-time high at 131.99 USD - Investing.com
PTGXProtagonist Therapeutics Inc Volatility & Greeks - Finviz
Protagonist Therapeutics updates its pipeline. PTGX focuses on peptide drug development - ad-hoc-news.de
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock - Yahoo Finance
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Protagonist Therapeutics awards new hires stock options and RSUs - Stock Titan
Protagonist Therapeutics stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
Why (PTGX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
Protagonist Therapeutics Inc (PTGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 4 Protagonist Therapeutics Inc For: 25 June By Investing.com - Investing.com Nigeria
Protagonist Therapeutics, Inc. Actuals & Estimates (NASDAQ:PTGX) - TradingView
Protagonist Therapeutics director Waddill sells $1.06m in stock By Investing.com - Investing.com Nigeria
Protagonist Therapeutics director Waddill sells $1.06m in stock - Investing.com
Director at Protagonist (NASDAQ: PTGX) trades 9,000 shares under 10b5-1 plan - Stock Titan
Protagonist Therapeutics stock hits all-time high at 124.97 USD By Investing.com - Investing.com South Africa
PTGX Forecast — Price Target — Prediction for 2027 - TradingView
Protagonist Therapeutics stock hits all-time high at 124.97 USD - Investing.com
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView
Why Is Silence Therapeutics Stock Soaring Wednesday?Silence Therapeutics (NASDAQ:SLN) - Benzinga
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Surging Institutional Buying Interest - Sahm
Form 144 PROTAGONIST THERAPEUTICS For: 23 June By Investing.com - Investing.com Nigeria
PTGX (NASDAQ) Form 144: Director-linked 9,000-share sales and option exercise - Stock Titan
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Protagonist Therapeutics Inc Azioni (PTGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Jun 23 '26 |
Sale |
117.94 |
9,000 |
1,061,460 |
7,825 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):